| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Friday, September 17, 2021 7:07:02 AM
Correct!
What I can’t understand is how anyone can think Cytodyn has any information of value if it WASN’T involved. Let’s think about this clearly. The price ran up BECAUSE Nader was pumping it every day with PR’s and Patterson’s TedTX. I remember sitting on my porch with neighbors watching it soar day after day, giddy with excitement. This was from FOMO and the COVID play!
This has EVERYTHING to do with Nader and big mouth. At the same time, HIV BLA hadn’t received an RTF yet and he was also pumping cancer! Make no mistake, I’ve read the Culper report. There is NOTHING in there that Cytodyn can point to that hasn’t proven true. For one to not believe that, point to one single success, EUA, positive trial results or approval! The truth may hurt but it’s the truth.
If the SEC suspected outsiders from doing this, they would have arrested them in about five minutes. That’s how long it would have taken for them to track down the trades to individuals and then look at them! Does any really think it takes 15 months? Gimme a break!
Look at the insiders who sold: CEO, CFO and wife of COB!! That’s stuff the SEC is looking at.
Short sellers see through the BS with over valued stock and make their play. They gambled and were right. Period! I was as pissed as anyone: I was sitting on 60k shares at about a $.80 average, many in the $.30 range then some when I sold/bought back after the Vyera announcement.
Comments that will put you in jail:
“Treeeple digit stock” while selling
“Theeees close” as I hold up 3 fat fingers
“Golden Quarter” that never happened
“Beautiful results”
“Magnificent Results”
“82% success” when knowingly failed to meet endpoints
“Mexico wants quick 25 patient study and hopefully quick approval”- hmmm, what happened
“Request EUA from UK”- ok, maybe it was just a verbal request
“10 BP offers on my desk”. The SEC will be asking to see those
“50 companies that want to finance us”- the SEC will want to see those too
“This week, we revenue generating”- then pivot on call.
Toxic lending from Fife who is BARRED by the SEC.
CEO making so many false statements that FDA literally had to slap him down and say stop saying Leronlimab is with “safe” or “effective”. Basically, stop lying about it!
So, if the manipulation had nothing to do with Nader or the company, they’d have nothing to ask them.
Nader is going down- make no mistake. This lates pump is nothing more than the recent warrant holders getting more bang for their buck.
For the record, I’m confident the Brazil trials will NOT yield any approval. Every trial has failed thus far and they will not touch a company that the FDA put on alert and the SEC/DOJ is investigating. They’ll be bankrupt before then anyway. The last round of financing hasn’t been approved, there are not enough authorized shares to sell (MORE DILUTION) and the cash burn is too rapid.
Shorts, continue sleeping well.
Grip
What I can’t understand is how anyone can think Cytodyn has any information of value if it WASN’T involved. Let’s think about this clearly. The price ran up BECAUSE Nader was pumping it every day with PR’s and Patterson’s TedTX. I remember sitting on my porch with neighbors watching it soar day after day, giddy with excitement. This was from FOMO and the COVID play!
This has EVERYTHING to do with Nader and big mouth. At the same time, HIV BLA hadn’t received an RTF yet and he was also pumping cancer! Make no mistake, I’ve read the Culper report. There is NOTHING in there that Cytodyn can point to that hasn’t proven true. For one to not believe that, point to one single success, EUA, positive trial results or approval! The truth may hurt but it’s the truth.
If the SEC suspected outsiders from doing this, they would have arrested them in about five minutes. That’s how long it would have taken for them to track down the trades to individuals and then look at them! Does any really think it takes 15 months? Gimme a break!
Look at the insiders who sold: CEO, CFO and wife of COB!! That’s stuff the SEC is looking at.
Short sellers see through the BS with over valued stock and make their play. They gambled and were right. Period! I was as pissed as anyone: I was sitting on 60k shares at about a $.80 average, many in the $.30 range then some when I sold/bought back after the Vyera announcement.
Comments that will put you in jail:
“Treeeple digit stock” while selling
“Theeees close” as I hold up 3 fat fingers
“Golden Quarter” that never happened
“Beautiful results”
“Magnificent Results”
“82% success” when knowingly failed to meet endpoints
“Mexico wants quick 25 patient study and hopefully quick approval”- hmmm, what happened
“Request EUA from UK”- ok, maybe it was just a verbal request
“10 BP offers on my desk”. The SEC will be asking to see those
“50 companies that want to finance us”- the SEC will want to see those too
“This week, we revenue generating”- then pivot on call.
Toxic lending from Fife who is BARRED by the SEC.
CEO making so many false statements that FDA literally had to slap him down and say stop saying Leronlimab is with “safe” or “effective”. Basically, stop lying about it!
So, if the manipulation had nothing to do with Nader or the company, they’d have nothing to ask them.
Nader is going down- make no mistake. This lates pump is nothing more than the recent warrant holders getting more bang for their buck.
For the record, I’m confident the Brazil trials will NOT yield any approval. Every trial has failed thus far and they will not touch a company that the FDA put on alert and the SEC/DOJ is investigating. They’ll be bankrupt before then anyway. The last round of financing hasn’t been approved, there are not enough authorized shares to sell (MORE DILUTION) and the cash burn is too rapid.
Shorts, continue sleeping well.
Grip
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
